RhumbLine Advisers
STOK icon

RhumbLine Advisers’s Stoke Therapeutics STOK Stock Holding History

RhumbLine Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Buy
75,931
+8,616
+13% +$277K ﹤0.01% 1833
2026
Q1 		$2.19M Buy
67,315
+4,901
+8% +$161K ﹤0.01% 1803
2025
Q4 		$1.98M Sell
62,414
-5,890
-9% -$177K ﹤0.01% 1883
2025
Q3 		$1.61M Buy
68,304
+1,885
+3% +$32.3K ﹤0.01% 2020
2025
Q2 		$754K Buy
66,419
+16,820
+34% +$160K ﹤0.01% 2395
2025
Q1 		$330K Buy
49,599
+225
+0.5% +$2.1K ﹤0.01% 2830
2024
Q4 		$545K Buy
49,374
+2,787
+6% +$34.2K ﹤0.01% 2629
2024
Q3 		$573K Sell
46,587
-1,273
-3% -$18K ﹤0.01% 2614
2024
Q2 		$647K Buy
47,860
+5,990
+14% +$80.9K ﹤0.01% 2483
2024
Q1 		$565K Buy
41,870
+899
+2% +$5.45K ﹤0.01% 2590
2023
Q4 		$215K Sell
40,971
-38
-0.1% -$162 ﹤0.01% 3156
2023
Q3 		$162K Sell
41,009
-1,166
-3% -$7.67K ﹤0.01% 3267
2023
Q2 		$448K Buy
42,175
+7,578
+22% +$80.6K ﹤0.01% 2756
2023
Q1 		$288K Buy
34,597
+406
+1% +$3.66K ﹤0.01% 2627
2022
Q4 		$316K Buy
34,191
+475
+1% +$4.94K ﹤0.01% 2660
2022
Q3 		$433K Buy
33,716
+1,865
+6% +$29.7K ﹤0.01% 2561
2022
Q2 		$421K Buy
31,851
+12,506
+65% +$190K ﹤0.01% 2585
2022
Q1 		$407K Buy
19,345
+1,362
+8% +$27.3K ﹤0.01% 2512
2021
Q4 		$431K Sell
17,983
-336
-2% -$8.02K ﹤0.01% 2570
2021
Q3 		$466K Buy
18,319
+849
+5% +$23.7K ﹤0.01% 2578
2021
Q2 		$588K Buy
17,470
+1,963
+13% +$69.4K ﹤0.01% 2495
2021
Q1 		$602K Sell
15,507
-165
-1% -$9.39K ﹤0.01% 2404
2020
Q4 		$971K Buy
15,672
+910
+6% +$41.7K ﹤0.01% 2141
2020
Q3 		$494K Sell
14,762
-2,115
-13% -$60.4K ﹤0.01% 2295
2020
Q2 		$402K Sell
16,877
-3,341
-17% -$79.3K ﹤0.01% 2441
2020
Q1 		$463K Buy
20,218
+12,279
+155% +$303K ﹤0.01% 2195
2019
Q4 		$225K Buy
+7,939
New +$200K ﹤0.01% 2711

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's STOK Position: Q2 2026 in Review

RhumbLine Advisers increased its Stoke Therapeutics (STOK) stake by 13% in Q2 2026, buying an estimated $277K and bringing the position to 75,931 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

RhumbLine Advisers first reported a position in STOK in Q4 2019 and has held it in 27 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • RhumbLine Advisers held 75,931 shares of Stoke Therapeutics worth $2.48M as of Q2 2026.
  • RhumbLine Advisers bought 8,616 Stoke Therapeutics shares in Q2 2026, an estimated $277K.
  • Stoke Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1833 holding.
  • RhumbLine Advisers first reported a position in Stoke Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.